AMAG Pharma (AMAG) Posts Q2 Loss of $0.40
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
August 3, 2017 7:02 AM EDTSecond quarter 2017 GAAP revenue increased 24% over same period last year
 IntrarosaTM (prasterone) now commercially available
 Completed Feraheme® (ferumoxytol) submission to FDA to broaden label beyond chronic kidney disease
 Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the quarter ended June 30, 2017. Total GAAP revenue for the second quarter of 2017 increased to a record $158.4 million, 24% higher than the same period... More
